Banner
for drugs
Identification
Name Magnesium oxide
Accession Number DB01377
Type small molecule
Groups approved
Description

Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]
Structure Thumb
Download: MOL | SDF | SMILES | InChI
Display: 2D Structure | 3D Structure
Synonyms Not Available
Synonyms Not Available
Salts Not Available
Brand names Not Available
Brand mixtures Not Available
Categories
  • Antacids
CAS number 1309-48-4
Weight Average: 40.304
Monoisotopic: 39.97995652
Chemical Formula MgO
InChI Key InChIKey=CPLXHLVBOLITMK-UHFFFAOYSA-N
InChI
InChI=1S/Mg.O
Plain Text
IUPAC Name
oxomagnesium
SMILES
O=[Mg]
Plain Text
Mass Spec Not Available
Taxonomy
Kingdom Inorganic
Classes
  • Inorganic Ions and Gases
Substructures
  • Inorganic Ions and Gases
Pharmacology
Indication Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
Pharmacodynamics Not Available
Mechanism of action The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.
Absorption Not Available
Volume of distribution Not Available
Protein binding Not Available
Metabolism Not Available
Route of elimination Not Available
Half life Not Available
Clearance Not Available
Toxicity Not Available
Affected organisms Not Available
Pathways Not Available
Pharmacoeconomics
Manufacturers Not Available
Packagers
Dosage forms
Form Route Strength
Liquid Oral
Powder Oral
Solution / drops Oral
Tablet Oral
Prices
Unit description Cost Unit
Phillips 500 mg caplet 0.18 USD caplet
Magnesium oxide 400 mg tablet 0.13 USD tablet
Magnesium oxide 420 mg tablet 0.11 USD tablet
Magox 400 tablet 0.11 USD tablet
Mag-oxide 400 mg tablet 0.09 USD tablet
Magnesium oxide powder heavy 0.05 USD g
Magnesium oxide 500 mg tablet 0.04 USD tablet
Maox 420 mg tablet 0.04 USD tablet
Magnesium oxide 250 mg tablet 0.03 USD tablet
Patents Not Available
Properties
State solid
Melting point Not Available
Experimental Properties Not Available
Predicted Properties
Property Value Source
water solubility ALOGPS
logP 0 ALOGPS
logP -1.1 ChemAxon Molconvert
logS 0 ALOGPS
pKa 0 ChemAxon Molconvert
hydrogen acceptor count 1 ChemAxon Molconvert
hydrogen donor count 0 ChemAxon Molconvert
polar surface area 17.07 ChemAxon Molconvert
rotatable bond count 0 ChemAxon Molconvert
refractivity 1.44 ChemAxon Molconvert
polarizability 2.88 ChemAxon Molconvert
References
Synthesis Reference Not Available
General Reference
  1. Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. Pubmed
  2. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. Pubmed
External Links
Resource Link
KEGG Drug D01167 Link_out
KEGG Compound C12567 Link_out
PubChem Compound 14792 Link_out
PubChem Substance 46504815 Link_out
ChemSpider 14108 Link_out
ChEBI 31794 Link_out
ChEMBL 31794 Link_out
PharmGKB PA450286 Link_out
Drug Product Database 39365 Link_out
Drugs.com http://www.drugs.com/cdi/magnesium-oxide.html Link_out
Wikipedia http://en.wikipedia.org/wiki/Magnesia Link_out
ATC Codes
  • A12CC10
AHFS Codes
  • 88:29.00*
  • 92:02.00*
PDB Entries Not Available
FDA label Not Available
MSDS Not Available
Interactions
Drug Interactions
Drug Interaction
Amprenavir The antiacid decreases the absorption of amprenavir
Atazanavir This gastric pH modifier decreases the levels/effects of atazanavir
Chloroquine The antiacid decreases the absorption of chloroquine
Ciprofloxacin Formation of non-absorbable complexes
Clodronate Formation of non-absorbable complexes
Dapsone Formation of non-absorbable complexes
Delavirdine The antiacid decreases the effect of delavirdine
Demeclocycline Formation of non-absorbable complexes
Doxycycline Formation of non-absorbable complexes
Etidronic acid Formation of non-absorbable complexes
Fosamprenavir The antiacid decreases the absorption of amprenavir
Gatifloxacin Formation of non-absorbable complexes
Gemifloxacin Formation of non-absorbable complexes
Grepafloxacin Formation of non-absorbable complexes
Ibandronate Formation of non absorbable complexes
Indinavir The antacid decreases the absorption of indinavir
Itraconazole The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
Ketoconazole The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption.
Levofloxacin Formation of non-absorbable complexes
Minocycline Formation of non-absorbable complexes
Moxifloxacin Formation of non-absorbable complexes
Norfloxacin Formation of non-absorbable complexes
Ofloxacin Formation of non-absorbable complexes
Tiludronate The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours.
Trovafloxacin Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction.
Food Interactions Not Available
Comments
Drug created on July 06, 2007 14:30 / Updated on February 14, 2012 11:47